An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine

BACKGROUND Cognitive operations including pre-attentive sensory processing are markedly impaired in patients with schizophrenia (SCZ) but evidence significant interindividual heterogeneity, which moderates treatment response with nicotinic acetylcholine receptor (nAChR) agonists. Previous studies in healthy volunteers have shown baseline-dependency effects of the α7 nAChR agonist cytidine 5'-diphosphocholine (CDP-choline) administered alone and in combination with a nicotinic allosteric modulator (galantamine) on auditory deviance detection measured with the mismatch negativity (MMN) event-related potential (ERP). AIM The objective of this pilot study was to assess the acute effect of this combined α7 nAChR-targeted treatment (CDP-choline/galantamine) on speech MMN in patients with SCZ (N = 24) stratified by baseline MMN responses into low, medium, and high baseline auditory deviance detection subgroups. METHODS Patients with a stable diagnosis of SCZ attended two randomized, double-blind, placebo-controlled and counter-balanced testing sessions where they received a placebo or a CDP-choline (500 mg) and galantamine (16 mg) treatment. MMN ERPs were recorded during the presentation of a fast multi-feature speech MMN paradigm including five speech deviants. Clinical measures were acquired before and after treatment administration. RESULTS While no main treatment effect was observed, CDP-choline/galantamine significantly increased MMN amplitudes to frequency, duration, and vowel speech deviants in low group individuals. Individuals with higher positive and negative symptom scale negative, general, and total scores expressed the greatest MMN amplitude improvement following CDP-choline/galantamine. CONCLUSIONS These baseline-dependent nicotinic effects on early auditory information processing warrant different dosage and repeated administration assessments in patients with low baseline deviance detection levels.

[1]  A. González-Pinto,et al.  Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms , 2021, Frontiers in Psychiatry.

[2]  V. Knott,et al.  The acute dose and baseline amplitude-dependent effects of CDP-choline on deviance detection (MMN) in chronic schizophrenia: A pilot study. , 2021, Experimental and clinical psychopharmacology.

[3]  V. Knott,et al.  Interaction of Background Noise and Auditory Hallucinations on Phonemic Mismatch Negativity (MMN) and P3a Processing in Schizophrenia , 2020, Frontiers in Psychiatry.

[4]  N. Swerdlow,et al.  Hierarchical Pathways from Sensory Processing to Cognitive, Clinical, and Functional Impairments in Schizophrenia. , 2020, Schizophrenia bulletin.

[5]  V. Knott,et al.  CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study , 2020, Psychopharmacology.

[6]  A. Terry,et al.  α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future , 2020, Neuropharmacology.

[7]  J. Lieberman,et al.  Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients , 2020, Neuropsychopharmacology.

[8]  E. Albuquerque,et al.  Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects , 2019, Psychopharmacology.

[9]  D. Javitt,et al.  Bimodal distribution of tone-matching deficits indicates discrete pathophysiological entities within the syndrome of schizophrenia , 2019, Translational Psychiatry.

[10]  J. Barnett,et al.  The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia , 2019, Front. Psychiatry.

[11]  D. Salisbury,et al.  The neurophysiology of schizophrenia: Current update and future directions. , 2019, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[12]  D. Javitt,et al.  Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia , 2019, Schizophrenia Research.

[13]  V. Knott,et al.  NMDA Receptor Antagonist Effects on Speech-Related Mismatch Negativity and Its Underlying Oscillatory and Source Activity in Healthy Humans , 2019, Front. Pharmacol..

[14]  D. Javitt,et al.  Hierarchical deficits in auditory information processing in schizophrenia , 2019, Schizophrenia Research.

[15]  V. Knott,et al.  Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers , 2019, Journal of psychopharmacology.

[16]  I. Hernádi,et al.  Facilitation and inhibition of firing activity and N-methyl-D-aspartate-evoked responses of CA1 hippocampal pyramidal cells by alpha7 nicotinic acetylcholine receptor selective compounds in vivo , 2019, bioRxiv.

[17]  K. Kasai,et al.  Mismatch negativity (MMN) as a tool for translational investigations into early psychosis: A review. , 2019, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[18]  V. Knott,et al.  Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia. , 2019, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[19]  Korey P. Wylie,et al.  Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia. , 2018, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[20]  J. Kantrowitz.  N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia , 2018, Schizophrenia Research.

[21]  M. Afarideh,et al.  Citicoline (CDP‐choline) add‐on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double‐blind, randomized placebo‐controlled trial , 2018, Human psychopharmacology.

[22]  Brian Kirkpatrick,et al.  Schizophrenia heterogeneity revisited: Clinical, cognitive, and psychosocial correlates of statistically-derived negative symptoms subgroups. , 2018, Journal of psychiatric research.

[23]  D. Javitt,et al.  Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia , 2018, Schizophrenia Research.

[24]  D. Javitt,et al.  Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms , 2018, Schizophrenia Research.

[25]  D. Bertrand,et al.  The wonderland of neuronal nicotinic acetylcholine receptors , 2017, Biochemical pharmacology.

[26]  Tao-yi Yang,et al.  The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials , 2017, Acta pharmaceutica Sinica. B.

[27]  I. Hernádi,et al.  Alpha7 Nicotinic Acetylcholine Receptors Play a Predominant Role in the Cholinergic Potentiation of N-Methyl-D-Aspartate Evoked Firing Responses of Hippocampal CA1 Pyramidal Cells , 2017, Front. Cell. Neurosci..

[28]  J. Smucny,et al.  Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging , 2017, Journal of psychopharmacology.

[29]  M. Bloch,et al.  Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[30]  J. Brunelin,et al.  Tone-matching ability in patients with schizophrenia: A systematic review and meta-analysis , 2017, Schizophrenia Research.

[31]  R. Freedman,et al.  First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288 , 2017, Journal of psychopharmacology.

[32]  Michael F. Green,et al.  Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia , 2017, JAMA psychiatry.

[33]  John M. Davis,et al.  Dose Equivalents for Antipsychotic Drugs: The DDD Method. , 2016, Schizophrenia bulletin.

[34]  V. Knott,et al.  Cholinergic modulation of auditory P3 event-related potentials as indexed by CHRNA4 and CHRNA7 genotype variation in healthy volunteers , 2016, Neuroscience Letters.

[35]  R. Metherate,et al.  Synaptic interactions and inhibitory regulation in auditory cortex , 2016, Biological Psychology.

[36]  R. Näätänen,et al.  Mismatch negativity (MMN) as biomarker predicting psychosis in clinically at-risk individuals , 2016, Biological Psychology.

[37]  C. Molina,et al.  Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke , 2016, International journal of molecular sciences.

[38]  T. Rosburg,et al.  The effects of ketamine on the mismatch negativity (MMN) in humans – A meta-analysis , 2016, Clinical Neurophysiology.

[39]  L. Jones,et al.  Cognitive mechanisms associated with auditory sensory gating , 2016, Brain and Cognition.

[40]  N. Swerdlow,et al.  Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis , 2016, Neuropsychopharmacology.

[41]  S. Dehaene,et al.  Event-Related Potential, Time-frequency, and Functional Connectivity Facets of Local and Global Auditory Novelty Processing: An Intracranial Study in Humans. , 2015, Cerebral cortex.

[42]  L. Rueter,et al.  Nicotinic modulation of auditory evoked potential electroencephalography in a rodent neurodevelopmental model of schizophrenia. , 2015, Biochemical pharmacology.

[43]  V. Knott,et al.  The separate and combined effects of monoamine oxidase A inhibition and nicotine on the mismatch negativity event related potential , 2015, Pharmacology Biochemistry and Behavior.

[44]  T. Werge,et al.  Association Study of CHRNA7 Promoter Variants with Sensory and Sensorimotor Gating in Schizophrenia Patients and Healthy Controls: A Danish Case–Control Study , 2015, NeuroMolecular Medicine.

[45]  A. Malhotra.  Dissecting the Heterogeneity of Treatment Response in First-Episode Schizophrenia , 2015, Schizophrenia bulletin.

[46]  Robert Freedman,et al.  The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function , 2015, Neuropharmacology.

[47]  Daniel C. Javitt,et al.  Auditory dysfunction in schizophrenia: integrating clinical and basic features , 2015, Nature Reviews Neuroscience.

[48]  K. Hashimoto.  Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker , 2015, Current pharmaceutical design.

[49]  Verner Knott,et al.  An acute dose, randomized trial of the effects of CDP-Choline on Mismatch Negativity (MMN) in healthy volunteers stratified by deviance detection level , 2015 .

[50]  D. Javitt,et al.  Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosis , 2015, Schizophrenia Research.

[51]  Verner Knott,et al.  Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers , 2015, Pharmacology Biochemistry and Behavior.

[52]  P. Nishtala,et al.  Comparison of Anticholinergic Risk Scales and Associations with Adverse Health Outcomes in Older People , 2015, Journal of the American Geriatrics Society.

[53]  Robert Freedman,et al.  Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. , 2015, The American journal of psychiatry.

[54]  V. Knott,et al.  CDP-choline: Effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression , 2014, Journal of psychopharmacology.

[55]  Antigona Martinez,et al.  Reading deficits in schizophrenia and individuals at high clinical risk: relationship to sensory function, course of illness, and psychosocial outcome. , 2014, The American journal of psychiatry.

[56]  V. Knott,et al.  Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study , 2014, Human psychopharmacology.

[57]  Kristen M. Mackowick,et al.  Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[58]  J. Ford,et al.  Automatic Auditory Processing Deficits in Schizophrenia and Clinical High-Risk Patients: Forecasting Psychosis Risk with Mismatch Negativity , 2014, Biological Psychiatry.

[59]  J. Ford,et al.  Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans , 2013, Front. Psychiatry.

[60]  P. Michie,et al.  Mismatch Negativity: Translating the Potential , 2013, Front. Psychiatry.

[61]  M. Geyer,et al.  Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. , 2013, Biochemical pharmacology.

[62]  Sakae Takahashi,et al.  Heterogeneity of schizophrenia: Genetic and symptomatic factors , 2013, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[63]  K. Kasai,et al.  Mismatch Negativity as a “Translatable” Brain Marker Toward Early Intervention for Psychosis: A Review , 2013, Front. Psychiatry.

[64]  S. Deutsch,et al.  Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy , 2013, Schizophrenia Research.

[65]  V. Knott,et al.  Baseline dependency of nicotine’s sensory gating actions: similarities and differences in low, medium and high P50 suppressors , 2013, Journal of psychopharmacology.

[66]  S. Schmid,et al.  Sensorimotor gating and spatial learning in α7‐nicotinic receptor knockout mice , 2013, Genes, brain, and behavior.

[67]  V. Knott,et al.  Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness , 2012, Schizophrenia Research.

[68]  V. Knott,et al.  Nicotine and the hallucinating brain: Effects on mismatch negativity (MMN) in schizophrenia , 2012, Psychiatry Research.

[69]  Pejman Sehatpour,et al.  Differential Relationships of Mismatch Negativity and Visual P1 Deficits to Premorbid Characteristics and Functional Outcome in Schizophrenia , 2012, Biological Psychiatry.

[70]  A. Markou,et al.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits , 2012, Neuropharmacology.

[71]  Michael F. Green,et al.  Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS. , 2012, Schizophrenia bulletin.

[72]  V. Knott,et al.  Effects of auditory hallucinations on the mismatch negativity (MMN) in schizophrenia as measured by a modified 'optimal' multi-feature paradigm. , 2011, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[73]  Michael Wagner,et al.  Prediction of Psychosis by Mismatch Negativity , 2011, Biological Psychiatry.

[74]  D. Braff.  Gating in Schizophrenia: From Genes to Cognition (to Real World Function?) , 2011, Biological Psychiatry.

[75]  S. Erb,et al.  Age-related effects of acute nicotine on behavioural and neuronal measures of anxiety , 2010, Behavioural Brain Research.

[76]  Paavo Alku,et al.  Fast multi-feature paradigm for recording several mismatch negativities (MMNs) to phonetic and acoustic changes in speech sounds , 2009, Biological Psychology.

[77]  C. Arango,et al.  Antipsychotic effects on auditory sensory gating in schizophrenia patients , 2009, European Neuropsychopharmacology.

[78]  M. Kisley,et al.  Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform. , 2009, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[79]  R. Bevins,et al.  Individual differences in responses to nicotine: tracking changes from adolescence to adulthood , 2009, Acta Pharmacologica Sinica.

[80]  Michael F. Green,et al.  Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. , 2009, Schizophrenia bulletin.

[81]  Richard S. Ehrlichman,et al.  Deviance-elicited Changes in Event-related Potentials are Attenuated by Ketamine in Mice , 2008, Journal of Cognitive Neuroscience.

[82]  B. Pollock,et al.  Anticholinergic Activity of 107 Medications Commonly Used by Older Adults , 2008, Journal of the American Geriatrics Society.

[83]  Risto Näätänen,et al.  Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats , 2008, Brain Research.

[84]  S. Deutsch,et al.  Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective α7 nicotinic acetylcholine receptor agonist strategy , 2008, European Neuropsychopharmacology.

[85]  Nina R. Schooler,et al.  First Administration of Cytidine Diphosphocholine and Galantamine in Schizophrenia: A Sustained &agr;7 Nicotinic Agonist Strategy , 2008, Clinical neuropharmacology.

[86]  James M Gold,et al.  Galantamine for the treatment of cognitive impairments in people with schizophrenia. , 2008, The American journal of psychiatry.

[87]  A. Olincy,et al.  Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men , 2007 .

[88]  J. Lasalde-Dominicci,et al.  Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking , 2007, Cellular and Molecular Neurobiology.

[89]  T. Stroup.  Heterogeneity of treatment effects in schizophrenia. , 2007, The American journal of medicine.

[90]  Valer Jurcak,et al.  10/20, 10/10, and 10/5 systems revisited: Their validity as relative head-surface-based positioning systems , 2007, NeuroImage.

[91]  Daniel C. Javitt,et al.  Reading impairment and visual processing deficits in schizophrenia , 2006, Schizophrenia Research.

[92]  R. Freedman,et al.  Genetics of Chromosome 15q13-q14 in Schizophrenia , 2006, Biological Psychiatry.

[93]  K. Stephan,et al.  Nicotinic modulation of human auditory sensory memory: Evidence from mismatch negativity potentials. , 2006, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[94]  D. Umbricht,et al.  Mismatch negativity in schizophrenia: a meta-analysis , 2005, Schizophrenia Research.

[95]  C. Elger,et al.  Subdural recordings of the mismatch negativity (MMN) in patients with focal epilepsy. , 2005, Brain : a journal of neurology.

[96]  E. Kirino,et al.  Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity , 2005, Pharmacology Biochemistry and Behavior.

[97]  A. Olincy,et al.  Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. , 2005, The American journal of psychiatry.

[98]  D. Braff,et al.  Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. , 2005, Archives of general psychiatry.

[99]  T. Petros,et al.  Effects of transdermal nicotine on prose memory and attention in smokers and nonsmokers , 2005, Physiology & Behavior.

[100]  Robert Freedman,et al.  Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. , 2004, The American journal of psychiatry.

[101]  R. Näätänen,et al.  The mismatch negativity (MMN): towards the optimal paradigm , 2004, Clinical Neurophysiology.

[102]  R. Dempsey,et al.  Effects of Citicoline on Phospholipid and Glutathione Levels in Transient Cerebral Ischemia , 2001, Stroke.

[103]  D. Javitt.  Intracortical Mechanisms of Mismatch Negativity Dysfunction in Schizophrenia , 2000, Audiology and Neurotology.

[104]  A. Nordberg,et al.  Decreased Protein Levels of Nicotinic Receptor Subunits in the Hippocampus and Temporal Cortex of Patients with Alzheimer’s Disease , 2000, Journal of neurochemistry.

[105]  K. Perkins,et al.  Baseline-dependency of nicotine effects: a review. , 1999, Behavioural pharmacology.

[106]  R. Kerwin,et al.  Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia , 1999, Journal of neurochemistry.

[107]  G. Goldstein,et al.  Relations between cognitive and symptom profile heterogeneity in schizophrenia. , 1999, The Journal of nervous and mental disease.

[108]  C. Schroeder,et al.  Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[109]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[110]  A. Ganong,et al.  Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors , 1984, Brain Research.

[111]  H. Wigström,et al.  A possible correlate of the postsynaptic condition for long-lasting potentiation in the guinea pig hippocampus in vitro , 1984, Neuroscience Letters.

[112]  E Donchin,et al.  A new method for off-line removal of ocular artifact. , 1983, Electroencephalography and clinical neurophysiology.